Skip to main content
Article thumbnail
Location of Repository

Hydrocortisone therapy for patients with septic shock

By Charles L. Sprung, Djillali Annane, Didier Keh, Rui Moreno, Mervyn Singer, Klaus Freivogel, Yoram G. Weiss, Julie Benbenishy, Armin Kalenka, Helmuth Forst, Pierre-Francois Laterre, Konrad Reinhart, Didier Payen, Josef Briegel, Brian Cuthbertson and CORTICUS Study Group

Abstract

Background Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only in patients who remained hypotensive after fluid and vasopressor resuscitation and whose plasma cortisol levels did not rise appropriately after the administration of corticotropin. Methods In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 patients to receive 50 mg of intravenous hydrocortisone and 248 patients to receive placebo every 6 hours for 5 days; the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test. Results Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin (125 in the hydrocortisone group and 108 in the placebo group). At 28 days, there was no significant difference in mortality between patients in the two study groups who did not have a response to corticotropin (39.2% in the hydrocortisone group and 36.1% in the placebo group, P=0.69) or between those who had a response to corticotropin (28.8% in the hydrocortisone group and 28.7% in the placebo group, P=1.00). At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P=0.51). In the hydrocortisone group, shock was reversed more quickly than in the placebo group. However, there were more episodes of superinfection, including new sepsis and septic shock. Conclusions Hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not have a response to corticotropin, although hydrocortisone hastened reversal of shock in patients in whom shock was reversed. (ClinicalTrials.gov number, NCT00147004 [ClinicalTrials.gov] .)Peer reviewedPublisher PD

Topics: Anti-inflammatory Agents, Hydrocortisone, Shock, Septic, RC Internal medicine
Publisher: Massachusetts Medical Society.
Year: 2008
DOI identifier: 10.1056/NEJMoa071366
OAI identifier: oai:aura.abdn.ac.uk:2164/274
Journal:

Suggested articles

Citations

  1. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotrophin. JAMA 2000;283:1038-1045. 29 20. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patient.
  2. (1999). Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia
  3. Cardiovascular management of septic shock.
  4. (1988). CDC definitions for nosocomial infections.
  5. (1995). Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med
  6. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.
  7. Current epidemiology of septic shock. The CUB-Rea network.
  8. Current Infectious Disease Reports 2006;8:346-50. 3. Matot I, Sprung CL. Definition of sepsis. Sprung CL, Bernard GR, Dellinger RP (Editors). In: Guidelines for the management of severe sepsis and septic shock.
  9. Cuthbertson reports having served as a consultant, having received grant support and having been paid lecture fees by
  10. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
  11. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care.
  12. (2001). Guidelines for the management of severe sepsis and septic shock. Intensive Care Med
  13. High-dose antihrombin III in severe sepsis. A randomized controlled trial.
  14. (2004). Hospital mortality and resource use in subgroups of the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit Care Med
  15. (2006). Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab.
  16. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.
  17. (2001). Intensive Care Med
  18. Intensive insulin therapy in critically ill patients.
  19. (2005). Low dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med
  20. Management of sepsis.
  21. (2004). Meta-analysis: The effects of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med
  22. (2005). Nonopioid Anesthetics In:
  23. Paresis acquired in the intensive care unit: a prospective multicenter study.
  24. (2001). Principles and practice of endocrinology and metabolism. 3 rd Edition. Lippincott, Williams & Wilkins.
  25. (1995). Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med
  26. (1976). Steroids in the treatment of clinical septic shock. Ann Surg
  27. (1999). Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single center study. Crit Care Med
  28. Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock.
  29. (1984). The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study.
  30. (1998). Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentric, prospective study. Crit Care Med

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.